Hasil Pencarian  ::  Simpan CSV :: Kembali

"Latar belakang: Rehospitalisasi 30 hari pada gagal jantung menyebabkan perburukan prognosis dan paling sering terjadi karena kongesti hemodinamik yang ditandai oleh tekanan pengisian ventrikel kiri (left ventricular end diastolic pressure/LVEDP) persisten tinggi. Oleh karena itu, dekongesti komplit harus dipastikan sebelum pasien pulang dari perawatan. Salah satu modalitas yang potensial adalah skor SAFE melalui evaluasi 3 komponen kongesti hemodinamik, yaitu: pompa (ejection fraction/EF), pipa (internal jugular vein collapsibility index/IJVCI dan inferior vena cava/IVC) dan jaringan interstisial (B-lines). Pada studi ini, rerata E/e’ ditambahkan pada skor SAFE dengan pertimbangan nilai prognostik rerata E/e’ dalam memprediksi kejadian rehospitalisasi.Tujuan: Membandingkan skor SAFE dan skor SAFE+rerata E/e’ dalam memprediksi rehospitalisasi 30 hari terkait gagal jantung akut.Metode: Dilakukan studi kohort prospektif dengan melibatkan 82 orang pasien gagal jantung akut yang dirawat di RSJPDHK. Analisis bivariat dan multivariat dilakukan untuk membandingkan kemampuan prediksi skor SAFE dan skor SAFE+rerata E/e’ terhadap rehospitalisasi 30 hari terkait gagal jantung akut.Hasil: Insidensi rehospitalisasi 30 hari terkait gagal jantung akut mencapai 19,5%. Kurva Kaplan-Meier menunjukkan rehospitalisasi lebih rendah pada kondisi euvolemia daripada hipervolemia (p 0,003). Skor SAFE+rerata E/e’ memiliki kemampuan prediksi rehospitalisasi 30 hari yang lebih baik daripada skor SAFE (AUC 0,77 [95% CI: 0,64 – 0,89] vs AUC 0,74 [95% CI: 0,62 – 0,85]).Kesimpulan: Skor SAFE+rerata E/e’ memiliki kemampuan prediksi rehospitalisasi 30 hari terkait gagal jantung akut yang lebih baik daripada skor SAFE.

---

Background: Short-term-rehospitalization worsens prognosis and frequently occurs due to persistently high LVEDP (hemodynamic congestion) among patients with heart failure (HF). Therefore, it is necessary to ascertain complete decongestion prior to hospital discharge. SAFE score is a potential scoring system to do so because it measures 3 main components of hemodynamic congestion: pump (EF), pipe (IJVCI and IVC) and interstitial tissue (B-lines). In this study, average E/e’ is added to SAFE score considering its clinically significant prognostic value in predicting risk of rehospitalization among patients with HF.

Aim: To compare SAFE score and SAFE score+average E/e’ in predicting 30-day-acute HF (AHF)- related-rehospitalization.

Methods: A prospective cohort study was conducted by involving 82 patients admitted with AHF in National Cardiovascular Center Harapan Kita (NCCHK). Bivariate and multivariate analysis were done to find out which of the 2 models: SAFE score and SAFE score+average E/e’ could better predict risk of 30-day-AHF-related-rehospitalization.

Results: The incidence of 30-day-AHF-related-rehospitalization in this study was 19,5%. By using Kaplan-Meier curve, we identified significantly lower 30-day-AHF-related-rehospitalization in patients discharged with euvolemia than those with hypervolemia (p 0,003). SAFE score+average E/e’ had better predictive properties than SAFE score regarding 30-day-AHF-related-rehospitalization (AUC 0,77 [95% CI: 0,64 – 0,89] vs AUC 0,74 [95% CI: 0,62 – 0,85]).

Conclusion: SAFE score+average E/e’ had better predictive properties than SAFE score regarding 30- day-AHF-related-rehospitalization."

"Latar belakang: Rehospitalisasi 30 hari pada gagal jantung menyebabkan perburukan prognosis dan paling sering terjadi karena kongesti hemodinamik yang ditandai oleh tekanan pengisian ventrikel kiri (left ventricular end diastolic pressure/LVEDP) persisten tinggi. Oleh karena itu, dekongesti komplit harus dipastikan sebelum pasien pulang dari perawatan. Salah satu modalitas yang potensial adalah skor SAFE melalui evaluasi 3 komponen kongesti hemodinamik, yaitu: pompa (ejection fraction/EF), pipa (internal jugular vein collapsibility index/IJVCI dan inferior vena cava/IVC) dan jaringan interstisial (B-lines). Pada studi ini, rerata E/e’ ditambahkan pada skor SAFE dengan pertimbangan nilai prognostik rerata E/e’ dalam memprediksi kejadian rehospitalisasi.Tujuan: Membandingkan skor SAFE dan skor SAFE+rerata E/e’ dalam memprediksi rehospitalisasi 30 hari terkait gagal jantung akut.Metode: Dilakukan studi kohort prospektif dengan melibatkan 82 orang pasien gagal jantung akut yang dirawat di RSJPDHK. Analisis bivariat dan multivariat dilakukan untuk membandingkan kemampuan prediksi skor SAFE dan skor SAFE+rerata E/e’ terhadap rehospitalisasi 30 hari terkait gagal jantung akut.Hasil: Insidensi rehospitalisasi 30 hari terkait gagal jantung akut mencapai 19,5%. Kurva Kaplan-Meier menunjukkan rehospitalisasi lebih rendah pada kondisi euvolemia daripada hipervolemia (p 0,003). Skor SAFE+rerata E/e’ memiliki kemampuan prediksi rehospitalisasi 30 hari yang lebih baik daripada skor SAFE (AUC 0,77 [95% CI: 0,64 – 0,89] vs AUC 0,74 [95% CI: 0,62 – 0,85]).Kesimpulan: Skor SAFE+rerata E/e’ memiliki kemampuan prediksi rehospitalisasi 30 hari terkait gagal jantung akut yang lebih baik daripada skor SAFE.

---

Background: Short-term-rehospitalization worsens prognosis and frequently occurs due to persistently high LVEDP (hemodynamic congestion) among patients with heart failure (HF). Therefore, it is necessary to ascertain complete decongestion prior to hospital discharge. SAFE score is a potential scoring system to do so because it measures 3 main components of hemodynamic congestion: pump (EF), pipe (IJVCI and IVC) and interstitial tissue (B-lines). In this study, average E/e’ is added to SAFE score considering its clinically significant prognostic value in predicting risk of rehospitalization among patients with HF.

Aim: To compare SAFE score and SAFE score+average E/e’ in predicting 30-day-acute HF (AHF)- related-rehospitalization.

Methods: A prospective cohort study was conducted by involving 82 patients admitted with AHF in National Cardiovascular Center Harapan Kita (NCCHK). Bivariate and multivariate analysis were done to find out which of the 2 models: SAFE score and SAFE score+average E/e’ could better predict risk of 30-day-AHF-related-rehospitalization.

Results: The incidence of 30-day-AHF-related-rehospitalization in this study was 19,5%. By using Kaplan-Meier curve, we identified significantly lower 30-day-AHF-related-rehospitalization in patients discharged with euvolemia than those with hypervolemia (p 0,003). SAFE score+average E/e’ had better predictive properties than SAFE score regarding 30-day-AHF-related-rehospitalization (AUC 0,77 [95% CI: 0,64 – 0,89] vs AUC 0,74 [95% CI: 0,62 – 0,85]).

Conclusion: SAFE score+average E/e’ had better predictive properties than SAFE score regarding 30- day-AHF-related-rehospitalization."

"Latar belakang: Pasien gagal jantung dengan penurunan fraksi ejeksi memiliki angka readmisi yang lebih tinggi dibandingkan dengan fraksi ejeksi normal, dan angka readmisi paling tinggi pada 30-hari pertama pascakeluar admisi sebelumnya. Sekitar 30% pasien dengan gagal jantung juga mengalami Diabetes Melitus (DM) Tipe-2. Sejauh ini, belum ada prediktor kejadian readmisi dalam 30-hari pada pasien dengan populasi tersebut di RSJPDHK, khususnya prediktor dari sisi klinis dan metabolik.Tujuan: Mengetahui prediktor klinis dan metabolik terhadap kejadian readmisi dalam 30-hari pada pasien Gagal Jantung Dekompensasi Akut (GJDA) dengan penurunan fraksi ejeksi dan DM tipe-2.Metode: Studi dilakukan secara kohort retrospektif, data diambil dari rekam medis berdasarkan admisi pasien yang memenuhi kriteria inklusi antara Januari 2016-Januari 2021. Luaran klinis terbagi menjadi kelompok readmisi dan kelompok non-readmisi. Luaran klinis yang dinilai adalah kejadian readmisi akibat perburukan kondisi gagal jantung pada 30-hari pascaadmisi terakhir di RSJPDHK. Dilakukan analisis multivariat untuk menentukan prediktor yang bermakna menentukan readmisi dalam 30-hariHasil: Dari total 747 subjek penelitian, 179 subjek termasuk ke dalam kelompok readmisi, dan 568 subjek termasuk ke dalam kelompok non-readmisi (angka readmisi 24%). Analisis regresi logistik multivariat menunjukkan bahwa faktor-faktor yang berhubungan dengan kejadian readmisi dalam 30-hari adalah: irama fibrilasi atrium (OR 2.616; 95% IK: 1.604-4.267; p 0.000), serta denyut jantung saat pulang rawat (OR 1.022; 95% IK: 1.005-1.039; p 0.010). Kadar gula darah post-prandial < 140 mg/dL menjadi prediktor protektif untuk kejadian readmisi dalam 30-hari (OR 0.528; 95% IK: 0.348-0.802; p 0.003).Kesimpulan: Dua faktor klinis yaitu irama fibrilasi atrium dan denyut jantung saat akhir masa rawat menjadi prediktor readmisi yang bermakna terhadap kejadian readmisi dalam 30-hari akibat perburukan kondisi gagal jantung, sedangkan kadar gula darah post-prandial < 140 mg/dL menjadi faktor protektif untuk kejadian readmisi 30-hari pada populasi pasien gagal jantung dengan penurunan fraksi ejeksi dan DM tipe-2.

---

Background: Patients Heart Failure with reduced Ejection Fraction (HFrEF) had higher readmission rates than normal ejection fractions, and readmission rates were highest in the first 30-days post-admission. About 30% of patients with heart failure also have Type-2 Diabetes Mellitus (DM). So far, there is no predictors for the incidence of 30-days readmission in patients with this kind of population in National Cardiovascular Centre Harapan Kita (NCCHK).

Objective: To determine the clinical and metabolic predictors of 30-days readmission in patients with Acute Decompensated Heart Failure (ADHF) with reduced ejection fraction and type-2 DM.

Methods: The study was conducted in a retrospective-cohort, data were taken from medical records based on admissions of patients who met the inclusion criteria between January 2016-January 2021. The clinical outcomes were divided into readmission and non-readmission groups. The clinical outcome assessed was the incidence of readmission due to worsening of the condition of heart failure at 30-days after the last admission at NCCHK. Multivariate analysis was performed to determine significant predictors for 30-day readmission.

Result: Of the total 747 research subjects, 179 subjects were included in the readmission group, and 568 subjects included in the non-readmission group (readmission rate 24%). Multivariate logistic regression analysis showed that the factors associated at 30-days readmission were: atrial fibrillation rhythm (OR 2.616; 95% CI: 1.604-4,267; p 0.000), heart rate at discharge (OR 1.022; 95% CI: 1.005-1.039; p 0.010). Post-prandial blood glucose level < 140 mg/dL was a protective predictor for 30-day readmission (OR 0.528; 95% CI: 0.348-0.802; p 0.003).

Conclusions: Two clinical factors, namely atrial fibrillation and heart rate at the end of hospitalization, were significant predictors of readmission in 30 days due to worsening of heart failure, while postprandial blood sugar levels < 140 mg/dL were protective factors for 30-days readmission in population of heart failure with reduced ejection fraction and type-2 DM."

"Latar Belakang: Infeksi COVID-19 merupakan penyakit dengan komplikasi multi-organ, salah satunya komplikasi kardiovaskular. Dengan kejadian gagal jantung akut sebagai komplikasi COVID-19 dengan mortalitas dan morbiditas yang tinggi, perlu dilakukan identifikasi faktor-faktor yang berhubungan dengan terjadinya gagal jantung akut pada pasien COVID-19, khususnya pada derajat sedang – berat.Tujuan : Mengetahui prediktor gagal jantung akut pada pasien COVID-19 yang dirawat, khususnya derajat sedang – beratMetode : Metode penelitian bersifat kohort retrospektif. Luaran primer adalah kejadian gagal jantung akut saat perawatan. Terdapat 15 faktor klinis dan laboratoris yang dianalisis secara bivariat dan multivariat.Hasil: Dari total 208 subjek sesuai kriteria inklusi dan eksklusi, sebanyak 73 subjek (35%) mengalami episode gagal jantung akut saat perawatan. Riwayat gagal jantung kronik memiliki risiko 5,39 kali (95% IK: 1,76 – 16,51; p = 0,003) mengalami kejadian gagal jantung akut. Pasien dengan nilai TAPSE < 17 mm memiliki risiko 4,25 kali (95% IK: 1,13 – 16,07; p= 0,033) mengalami gagal jantung akut. Sedangkan pemakaian ACE-i/ARB memiliki risiko 0,16 kali (95% IK: 0,05 – 0,51; p = 0,002) untuk mengalami gagal jantung akut intraperawatan dibandingkan kelompok tanpa pemakaian ACE-i/ARB.Kesimpulan: Riwayat gagal jantung kronik, TAPSE < 17 mm, dan pemakaian ACE-i/ARB diidentifikasi sebagai prediktor kejadian gagal jantung akut pada pasien COVID-19.

---

Introduction: COVID-19 infection is a disease with multi-organ complications, including cardiovascular organ. As heart failure is one of COVID – 19 complications that has high morbidity and mortality, we need to identify factors that can predict acute heart failure in COVID – 19, especially in moderate to severe patients.

Objective : to determine predictors of acute heart failure in hospitalized COVID -19 patients

Method : This was a retrospective cohort study. The primary outcome was acute heart failure that happened during hospitalization. There were total of 16 clinical (age, sex, body mass index, hypertension, diabetes, smoking history, coronary artery disease, chronic kidney disease, chronic heart failure, chronic obstructive pulmonary disease, PaO2/FiO2 ratio, non-cardiogenic shock at admission, use of ACE-inhibitors/ARBs during hospitalization, ejection fraction, TAPSE) as well as 6 laboratory parameters (neutrophil - lymphocyte ratio, platelet - lymphocyte ratio, eGFR, D-Dimer, procalcitonin, CRP) that were used in statistical analysis.

Result: From total of 208 subjects with moderate – severe COVID-19, 73 (35%) had acute heart failure. The median time of developing heart failure is 4 ( 1 - 27) days. On multivariate analysis, patients with history of chronic heart failure exhibited a 5.39-fold higher risk of acute heart failure compared with no history of chronic heart failure (95% CI: 1.76 – 16.51; p = 0.003). The risk of acute heart failure was multiplied by 4.25 in patients that was presented with TAPSE <17 mm (95% CI: 1.13 – 16.07; p= 0.033). In contrast, use/continuation of ACE-inhibitors/angiotensin receptor blockers during hospitalization showed reduced risk of acute heart failure (16% of the risk developing acute heart failure compared with patients with no use of ACE-inhibitors/angiotensin receptor blockers). In subjects developing acute heart failure, the mortality rate was 67%, compared with 57% in subjects without acute heart failure (p = 0,028).

Conclusion: History of chronic heart failure, TAPSE <17 mm, and the use of ACE-inhibitors/angiotensin receptor blockers were identified as predictors of acute heart failure in hospitalized COVID-19 patients."

"Latar Belakang: COVID-19 menyebabkan respon inflamasi sistemik dan ganguan koagulasi yang memperberat disfungsi endotel dan destablisasi plak intrakoroner yang berhubungan dengan beban trombus tinggi sehingga menyebabkan morbiditas dan mortalitas yang tinggi. Pasien dengan COVID-19 dengan infark miokard akut dengan elevasi segmen ST (IMAEST) yang memiliki beban trombus tinggi dihubungkan dengan mortalitas jangka pendek yang lebih besar namun pengaruhnya terhadap mortalitas dengan waktu yang lebih lama masih belum jelas.Tujuan: Mengetahui hubungan COVID-19 dengan mortalitas 6 bulan pada pasien IMAEST dengan beban trombus tinggi (BTT) intrakoroner yang menjalani intervensi koroner perkutan (IKPP).Metode: Terdapat 124 pasien dengan IMAEST yang memiliki BTT intrakoroner yang menjalani IKPP pada periode April 2020 hingga November 2021 dianalisis secara retrospektif. BTT intrakoroner berdasarkan kriteria TIMI. Status COVID-19 positif atau negatif berdasarkan pemeriksaan laboratorium dan variabel lainnya dilihat hubungannya terhadap mortalitas 6 bulan dengan analisis kesintasan dan cox regresi.Hasil: Terdapat mortalitas tinggi pada pasien COVID-19 positif (31%) dibanding pasien COVID-19 negatif (4,2%) sampai dengan 6 bulan sejak admisi rumah sakit. Pasien dengan COVID-19 cenderung meninggal lebih besar dalam 6 bulan dibanding pasien tanpa COVID-19 (HR 8.45 IK95% 2.6- 27.5). Pada model akhir multivariat analisis, status COVID-19 positif merupakan prediktor independen terhadap kematian 6 bulan sejak admisi (HR 12,89 ; IK95%:3,34 – 49,76 ; p ≤ 0,001). Status COVID-19 positif pada pasien IMAEST dengan BTT intrakoroner yang menjalani IKPP ini juga mempengaruhi level kesintasan (survival rate) yang lebih rendah dalam 6 bulan.Kesimpulan: Terdapat hubungan antara COVID-19 dengan mortalitas 6 bulan pada pasien dengan IMAEST dengan BTT intrakoroner yang menjalani IKPP.

---

Background: COVID-19 causes systemic inflammatory response and disturbance in coagulation function which might give detrimental effect on endothelial dysfunction and instability of coronary plaque leading to high thrombus burden and affecting morbidity and mortality. Patients with COVID-19 with ST Elevation Myocardial Infarction (STEMI) that have Intracoronary High Thrombus Burden (IHTB) is reported to have higher intrahospital mortality but its impact on long-term mortality is still not known.

Objective: To determine whether COVID-19 is affecting 6 months mortality in STEMI patients with IHTB who undererwent Primary Percutanoeus Coronary Intervention (PPCI).

Methods: There were 124 patients with STEMI with IHTB who underwent PPCI form April 2020 to November 2021 from retrospective analysis. IHTB were classified according TIMI thrombus grade. COVID-19 status (positive or negative) were obtained according to laboratory results and other variables were analysed with cox regression analysis and survival analysis.

Results: Higher 6 months mortality rate from admission was found among COVID 19 patients compared to COVID-19 negative patients (31% vs 4,2%). The risk of death within 6 months from admission was higher in COVID-19 positive patients compared to COVID-19 negative patients ( HR 8.45 CI95% 2.6 -27.5, p < 0.001). In multivariate analysis, COVID-19 positive was independent predictor for 6 months mortality from admission ( HR 12.89 CI95% 3.34- 49.7 , p ≤ 0,001). Patients with COVID-19 positive were also had lower survival rate within 6 months from admission.

Conclusion: COVID-19 is associated with 6 months mortality from admission in patients with STEMI with IHTB who underwent PPCI."

"Latar Belakang: Tatalaksana pasien Penyakit jantung bawaan (PJB) dengan obstruksi Alur Keluar Ventrikel Kanan (AKVK) yang belum dapat dilakukan operasi reparasi adalah tindakan paliatif. Implantasi stent AKVK saat ini mulai menjadi alternatif pilihan.Tujuan: Mengetahui luaran klinis pasien anak usia 0-18 tahun dengan obstruksi infundibular AKVK dengan shunt ventrikel dibandingkan dengan operasi Modified Blalock-Thomas-Taussig Shunt (MBTTS).Metode: Studi kohort retrospektif dengan menggunakan data sekunder dari rekam medis pasien obstruksi AKVK disertai shunt ventrikel yang dilakukan implantasi stent AKVK atau MBTTS pada Desember 2019-Oktober 2022 di RS PJNHK. Dilakukan pemantauan selama perawatan, dilanjutkan dengan follow up 30 hari setelah tindakan.Hasil: Total 87 pasien diinklusikan pada penelitian ini; 29 pasien dilakukan implantasi stent AKVK, dan 58 pasien dilakukan tindakan MBTTS, median usia kelompok stent AKVK 29 (1-220) bulan, dan kelompok MBTTS 25,5 (6-227) bulan (p=0,739). Luaran klinis MACE pada kelompok stent AKVK vs MBTTS tidak berbeda, rehospitalisasi (1(3,4%) vs 0(0%), p=0,333), re-intervensi (3(10,3%) vs 6 (10,3%), p=1,000), kematian dalam 30 hari (3(10,3%) vs 2 (3,4%), p=0,340). Target saturasi oksigen tercapai tidak berbeda pada kedua kelompok stent AKVK vs MBTTS (93,1% vs 96,5 %, p=0,290). Lama rawat ICU pada kelompok stent AKVK dan MBTTS ( 2(0-43) hari vs 3,5(2-9) hari, p <0,001), total lama rawat RS antara kedua kelompok (6,5 (3-41) hari vs 7(4-24) hari, p=0,048) berbeda bermakna.Kesimpulan: Luaran klinis tindakan stent AKVK pada pasien anak dengan obstruksi AKVK dengan shunt ventrikel tidak berbeda dengan tindakan MBTTS pada MACE, pencapaian target saturasi oksigen paska tindakan, namun berbeda pada lama rawat di ICU dan total lama rawat di rumah sakit.

---

Background: The main treatment of Congenital heart disease (CHD) patient with right ventricular outflow tract (RVOT) obstruction with ventricular shunt who were unable to undergone surgical repair was palliative procedure. Implantation of RVOT stent has become an alternative option.

Objectives: To determine the characteristics and clinical outcomes of pediatric patients aged 0-18 years with infundibular RVOT obstruction with ventricular shunt compared with Modified Blalock-Thomas-Taussig Shunt (MBTTS) surgery.

Methods: This retrospective cohort study was using secondary data. Basic data was collected through medical records for patients with infundibular RVOT obstruction with ventricular shunt, which underwent RVOT stent implantation or MBTTS in the period of December 2019-October 2022 at the NCCHK. Monitoring was carried out during treatment and continued with follow-up within 30 days after the procedure.

Results: A total of 87 patients were included; 29 patients underwent RVOT stent implantation, and 58 patients underwent MBTTS, median age of RVOT stent group of 29 (1-220) months, and MBTTS group of 25,5 (6-227) months, (p=0,739). Initial clinical outcome of MACE in RVOT stent vs MBTTS group was not different, rehospitalisation (1 (3,4%) vs 0 (0%), p=0,333), re-intervention (3(10,3%) vs 6 (10,3%), p=1,000), and 30-day mortality (3(10,3%) vs 2 (3,4%), p=0,340). Achieved oxygen saturation target was in RVOT stent vs MBTTS was (93,1% vs 96,5 %, p=0,290). ICU length of stay (LOS) in RVOT stent group vs MBTTS was 2 (0-43 days) vs 3,5 (2-9 days), p <0,001, total hospital LOS was (6,5 (3-41 days) vs 7(4-24 days), p=0,048) was different significantly.

Conclusion: Initial clinical outcome in paediatric patients with RVOT obstruction with shunt who underwent RVOT stent or MBTTS was not different in MACE, achievement of oxygen saturation target, but significantly different in ICU LOS, and total hopital LOS"